Camm A J, Hellestrand K J, Nathan A W, Bexton R S
Drugs. 1985;29 Suppl 4:7-13. doi: 10.2165/00003495-198500294-00003.
Flecainide acetate depresses both the upstroke of the intracellular action potential and the rate of diastolic depolarisation in isolated tissue preparations of atrial myocardium. It produces no consistent effect on action potential duration. Predictably, in the human heart, studied by clinical cardiac electrophysiological techniques, conduction velocity through atrial myocardium, the atrioventricular (AV) node and anomalous tissue is depressed following flecainide administration. Refractoriness of normal atrial or AV nodal myocardium is not prolonged but the recovery time of anomalous or abnormal tissue is lengthened by the drug. In response to the intravenous injection of flecainide, atrial fibrillation (90%), atrial tachycardia (100%), intra-AV nodal tachycardia (89%) and atrioventricular re-entrant tachycardia (80%) are generally terminated, and although atrial flutter is slowed, only a small proportion (20%) is terminated. There is little experience of the long term treatment of supraventricular tachycardia with oral flecainide. However, preliminary results suggest that flecainide is equally effective in the treatment of both supraventricular and ventricular arrhythmias. Thus, flecainide acetate is a 'broad spectrum' antiarrhythmic agent.
醋酸氟卡尼可抑制心房肌分离组织标本中细胞内动作电位的上升支以及舒张期去极化速率。它对动作电位持续时间没有一致的影响。可以预见，在通过临床心脏电生理技术研究的人体心脏中，服用氟卡尼后，通过心房肌、房室（AV）结和异常组织的传导速度会降低。正常心房或房室结心肌的不应期不会延长，但该药物会延长异常或病变组织的恢复时间。静脉注射氟卡尼后，心房颤动（90%）、房性心动过速（100%）、房室结内心动过速（89%）和房室折返性心动过速（80%）通常会终止，虽然心房扑动会减慢，但只有一小部分（20%）会终止。口服氟卡尼长期治疗室上性心动过速的经验很少。然而，初步结果表明，氟卡尼在治疗室上性和室性心律失常方面同样有效。因此，醋酸氟卡尼是一种“广谱”抗心律失常药物。
